Interference with the expression of S1PR1 or STAT3 attenuates valvular damage due to rheumatic heart disease

Shenglin Xian1, Ang Chen1, Yunjiao Wu1

  • 1Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.

Insights

Rheumatic heart disease (RHD) involves valvular damage linked to sphingosine 1-phosphate receptor 1 (S1PR1) and signal transducer and activator of transcription 3 (STAT3). Modulating S1PR1 or STAT3 expression may reduce RHD-induced inflammation and fibrosis.

Area of Science:

  • Immunology
  • Cardiovascular Biology
  • Molecular Medicine

Background:

  • Rheumatic heart disease (RHD) pathogenesis is not fully understood.
  • Sphingosine 1-phosphate receptor 1 (S1PR1) and signal transducer and activator of transcription 3 (STAT3) are implicated in RHD-induced valvular damage through T helper 17 (Th17) cell differentiation.

Purpose of the Study:

  • To investigate if altering S1PR1 or STAT3 expression can attenuate valvular damage in a rat model of RHD.

Main Methods:

  • Established RHD rat model using inactivated group A Streptococcus (GAS).
  • Overexpressed S1PR1 using recombinant adeno-associated viral vectors.
  • Inhibited STAT3 expression using STAT3 small interfering RNA (siRNA).
  • Assessed molecular markers (mRNA, protein levels of S1PR1, STAT3, p-STAT3, RORγt, Col3a1, FSP1) and inflammatory/fibrotic indicators (IL-6, IL-17, H&E, Sirius Red staining).

Main Results:

  • RHD rats showed decreased S1PR1 expression and increased IL-6, IL-17, and p-STAT3 levels.
  • Increased valvular inflammation and fibrosis were observed in RHD rats.
  • S1PR1 overexpression and STAT3 inhibition reduced p-STAT3, IL-6, IL-17, and RORγt levels, mitigating valvular damage.

Conclusions:

  • S1PR1 and STAT3 play significant roles in RHD-induced valvular tissue damage.
  • Targeting S1PR1 or STAT3 expression may offer therapeutic strategies by modulating Th17 cell-related cytokines to attenuate RHD.
  • Further research into S1PR1 and STAT3 pathways is warranted for RHD treatment.

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
129
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
70
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
144
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
59
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
97
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
88